Changes of the ChIP-seq levels of the above proteins at promoters and enhancers upon JQ1 treatment are shown in Fig. 2D and genome-wide changes are shown in Additional file 1: Figure S2, A to F. Across the three cell lines, upon JQ1 treatment, the binding of BRD4 at both promoters and enhancers was almost completely depleted (> 95% loss of peaks; Fig. 2D, top), and the level of H3K27ac at both promoters and enhancers was reduced in all three cell lines (Fig. 2D, bottom); the latter finding is consistent with the analysis of another glioma cell type, diffuse intrinsic pontine glioma [44]. The gene discussed is BRD4; the disease is central nervous system cancer.